Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

PROVISTA and RADIENT REVERSE MERGER UPDATES.. THE TRUTH >>>>>>>>>>>>>>>>>>>>>>>>>....according to the LOI 2010 merger with Radient

A Must Read >>>>>

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111990692

Due Diligence and the FACTS for your Pleasure...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111990692

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112015600

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112015600

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112054372

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112110363


DC The Angel Investors bought Provista Diasgnostics before they got their reagents from LPath and ASU...The BT Test combined with DR-70 for the Lung Cancer and Breast Cancer was the reason they poured inm illions and now own 60 per cent of RXPC Stock.. ...With the money from the angel investors, Provista was now in a position to do the studies..DR-70 can detect 19 different types of cancer, that is the benefit of DR-70..Combined with Provista's IP it is a better test in all 19...Now Provista can get the New Generation test FDA approved more quickly...We are sitting on a "Diamond In The Rough" You understand....imo Wolf

****************************************************************
"completion of the deal within a timeframe that suits the needs of both Companies and shareholders."

Our needs will be fulfilled..All of the Above DC you understand....To bad some don't own shares..lol


According to Mr. Douglas MacLellan, Executive Chairman and CEO of RPC, "The detection benefit observed in this study represents a meaningful additional to tests available today. We are very encouraged by the potential benefit of this test to patients who are facing the deadly threat of lung cancer. As previously announced, RPC is actively engaged in acquisition negotiations with Provista and with the success of the deal; we expect to combine both companies to achieve a leadership presence in the global cancer diagnostics market."

On September 27, 2010 RPC signed an extension of its original agreement dated July 13, 2010 to merge with Provista Diagnostics Inc., making the agreement between Provista Diagnostics and Radient Pharmaceuticals effective through December 31, 2010. Both Companies have confirmed continued interest in the merger and to pursue completion of the deal within a timeframe that suits the needs of both Companies and shareholders.


http://salesandmarketingnetwork.com/news_release.php?pipe=0000ac177000191&ID=2031889
****************************************************************

guardiangel Wednesday, 03/25/15 02:30:58 AM
Re: guardiangel post# 28473
Post # of 28523

DEJA VU U Understand..Coming to a Cosco Near You..ahoooooooooooo


Q: What can you say about the pending acquisition of Provista?

Douglas MacLellan, CEO, Radient Pharmaceuticals: That’s obviously out there. One, we have a business relationship with Provista that looks very promising whether we buy them or not. So we have advanced the better part of the economic equation with cooperative agreements- with them- to develop the lung cancer test kit and they expect to be marketing that widely, at places like Costco and other retailers by the second quarter. That can be an enormously profitable business for us.

We have, right now, a cooperative agreement in place to do that without ever acquiring them. At the end of the day, would it be more interesting to have them as one of our subsidiaries? Yeah, we’ve thought so but we haven’t been in a financial position to complete that transaction. We may be in a financial position to do that in 2011. We need to determine whether we need a shareholder meeting, relative values, etc. But remember, even if we never do that we’ve got a great business relationship that can be enormously profitable.

http://www.biomedreports.com/2011012762916/radients-ceo-believes-company-should-qualify-to-continue-trading-on-the-amex.html

*****************************************************************


Onko-Sure in IRAN<<<>>SRL BREAST CANCER TEST IN ITALY

http://www.retenews24.it/rtn24/donna-2/prevenzione-tumori-creato-un-test-con-semplice-analisi-del-sangue-che-rivela-13-tipi-di-cancro-ecco-quale/




Prevention is the best weapon to defend themselves from cancer, but if this were not enough early diagnosis is fundamental to winning the battle against this evil.

In this regard has been developed a new diagnostic test, minimally invasive and expensive, able to discover the presence of 13 different types of cancer.

The test is carried out using a simple blood test, the analysis of which you can tell if cancer cells are present in the body, even if the eventual disease was in its early stages.

The exam, called Onko-Sure, it would be able to diagnose tumors in the colon, rectum, lung, liver, ovaries and many others.

To create it were the company's specialists SRL Diagnostics, led by Dr BR Das, which have concentrated on some protein fragments (FDP) that are produced from the degradation of fibrinogen.

The test allows you to track down these molecules that determine the action of cancer cells, and we hope to become, once implemented, an effective prevention tool available to all.


SRL is distributing Onko-Sure in EU including Italy, Spain, UK, Russia, Africa, Middle east, Turkey..etc. This is hw provista will get their Videssa Breast, Videssa Lung,to the markt etc..ahooooooooooooooooooooo


That's amore... L’analisi del sangue rileva 13 tipi di tumore

http://www.west-info.eu/it/analisi-del-sangue-13-tipi-tumore-cancro/2012-02-onkosure-fibrin-fdp-in-cancer-mm-2/

http://isna.ir/fa/news/91111508754/%D8%AA%D8%B4%D8%AE%DB%8C%D8%B5-13-%D9%86%D9%88%D8%B9-%D8%B3%D8%B1%D8%B7%D8%A7%D9%86-%D9%85%D8%AE%D8%AA%D9%84%D9%81-%D8%AA%D9%86%D9%87%D8%A7-%D8%A8%D8%A7-%DB%8C%DA%A9-%D8%A2%D8%B2%D9%85%D8%A7%DB%8C%D8%B4

http://www.asriran.com/fa/news/255614/%D8%AA%D8%B4%D8%AE%DB%8C%D8%B5-13-%D9%86%D9%88%D8%B9-%D8%B3%D8%B1%D8%B7%D8%A7%D9%86-%D9%85%D8%AE%D8%AA%D9%84%D9%81-%D8%AA%D9%86%D9%87%D8%A7-%D8%A8%D8%A7-%DB%8C%DA%A9-%D8%A2%D8%B2%D9%85%D8%A7%DB%8C%D8%B4-%D8%AE%D9%88%D9%86